Volumetric absorptive microsampling-LC-MS/MS assays for quantitation of giredestrant in dried human whole blood
Johnson et al.
The finding, in our words
LC-MS/MS assays successfully validated the quantitation of giredestrant in dried whole blood across 1 to 1000 ng/ml using Mitra and Tasso-M20 microsampling devices. Quantitation was unaffected by haematocrit, hyperlipidaemia or anticoagulants, with ambient stability documented for 84 days on Mitra and 28 days on Tasso-M20.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Volumetric absorptive microsampling (VAMS) using the Neoteryx Mitra device was validated for mitotane therapeutic drug monitoring across 1–50 mg/L, with acceptable haematocrit bias and one-week stability at room temperature. However, comparison with venous plasma showed poor correlation, suggesting home-based VAMS is of limited clinical value for mitotane unless a method-specific target range is established.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
The study developed and validated a reliable HPLC-MS method for quantifying multiple tyrosine kinase inhibitors from VAMS microsamples of capillary blood, showing acceptable accuracy, precision, and 28-day stability at -21°C, with results comparable to venous plasma in 194 samples from patients with solid tumours. This enables therapeutic drug monitoring using microsamples in oncology practice.
The study developed and validated a rapid LC-MS/MS method for quantifying cefazolin in capillary whole blood collected via VAMS, plasma, and plasma ultrafiltrate, showing robust performance across matrices and successful application in a pediatric pilot cohort for therapeutic drug monitoring.